Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430136 | 0.98 | RAB9A (0.40) | RAB9AEZH2L3MBTL1KDM5BPRMT6 | |
| SCHEMBL19429798 | 0.96 | RAB9A (0.42) | RAB9AEZH2L3MBTL1KDM5BPRMT6 | |
| SCHEMBL19430127 | 0.94 | RAB9A (0.44) | RAB9AEZH2L3MBTL1KDM5BPRMT6 | |
| SCHEMBL19429899 | 0.87 | RAB9A (0.43) | RAB9AEZH2L3MBTL1KDM5BPDE1A | |
| SCHEMBL19429934 | 0.87 | RAB9A (0.44) | RAB9AEZH2L3MBTL1KDM5BPRMT6 | |
| SCHEMBL17606388 | 0.87 | NTRK1 (0.46) | RAB9AEZH2L3MBTL1KDM5BPRMT6 | |
| SCHEMBL19421589 | 0.86 | RAB9A (0.45) | RAB9AEZH2L3MBTL1KDM5BPDE1A | |
| SCHEMBL19430097 | 0.86 | RAB9A (0.43) | RAB9AEZH2L3MBTL1KDM5BPDE1A | |
| SCHEMBL19430410 | 0.85 | PRMT6 (0.41) | RAB9AEZH2L3MBTL1KDM5BPRMT6 | |
| SCHEMBL19430133 | 0.85 | EZH2 (0.40) | RAB9AEZH2L3MBTL1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | RAB9A 1186/4885EZH2 28/4885L3MBTL1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.